Omnix Medical
Solution Type
Microbial Management, Antimicrobial Compound
Pathogens Addressed
Bacteria, Fungi, Yeasts
Sectors Served
Human Health, Veterinary, AgriFood, Environmental
Overview
Founded in 2015 and headquartered in Jerusalem, Israel, Omnix Medical is a clinical-stage biopharmaceutical company developing novel antimicrobial peptides for life-threatening drug-resistant infections. Its lead compound OMN6, which has received FDA Fast Track designation, targets Acinetobacter baumannii by disrupting bacterial cell membranes , a mechanism effective regardless of resistance genotype and with a low risk of triggering new resistance.
Stay Updated
Stay connected so that you don't miss the latest AMR insights and updates.
